 |
|
| Type | Public (OMX: LUN) |
|---|---|
| Founded | 1915 |
| Headquarters | Copenhagen, Denmark |
| Key people | Per Wold-Olsen (Chairman of the board), Ulf Wiinberg (President and CEO) |
| Industry | Pharmaceuticals |
| Revenue | DKK 11.282 billion (2008)[1] |
| Operating income | ▲ DKK 2.352 billion (2008)[1] |
| Profit | ▲ DKK 1.510 billion (2008)[1] |
| Employees | 5,210 (2008)[1] |
| Website | www.lundbeck.com |
H. Lundbeck A/S (commonly known simply as Lundbeck, OMX: LUN) is a Danish international pharmaceutical company engaged in the research and development, production, marketing, and sale of drugs for the treatment of psychiatric and neurological disorders, particularly fast-working, non-addictive anti-depressants for people who need to function while medicated.
The company was founded by Hans Lundbeck in 1915, and was initially a trading company supplying a variety of goods to the Danish market, including machinery for manufacturing, aluminium foil, artificial sweeteners, and photographic equipment.
Lundbeck entered the pharmaceutical market in 1924, importing medicines and cosmetics from companies based in other European and American countries. By the late 1930s, Lundbeck had begun to produce its own medicinal products and had established its own research department. Production continued during the Second World War, although it was limited due to a lack of raw materials.
After the war, Lundbeck continued to grow, and became a major international pharmaceutical company focusing on the production of drugs used to treat disorders and diseases of the central nervous system. In 2007, the company's revenue was €1.47 billion.
In 2009, Lundbeck completed the acquisition of Ovation Pharmaceuticals, a leading U.S. biopharmaceutical company that was founded in 2000 by Jeffrey Aronin and Dr. Joel E. Bernstein.
Key products are the selective serotonin reuptake inhibitor escitalopram, and memantine.
References
- ^ a b c d "Annual Report 2008". Lundbeck. http://www.e-pages.dk/lundbeck/157/fullpdf/1.pdf. Retrieved 2009-03-12.
See also
- Tarenflurbil, which the company had arranged for EU distribution rights on prior to termination of its development by Myriad
External links
|
|||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
